The success of CRISPR/Cas9-mediated gene editing in correcting COL1A1 pathogenic variants for OI serves as a valuable proof of concept for treating other collagen-related disorders and genetic bone diseases, highlighting the broader potential of precision gene therapy in regenerative medicine. The gene discussed is COL1A1; the disease is osteogenesis imperfecta.